Responses
ABSTRACT: Poster Session 1: Ovarian – Sunday, October 15, 2006
0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients
Compose a Response to This Article
Other responses
No responses have been published for this article.